Moxifloxacin: a respiratory fluoroquinolone

Item

http://www.wikidata.org/entity/Q57778170

description

im Juni 2008 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в червні 2008

@uk

name

Moxifloxacin: a respiratory fluoroquinolone

@en

Moxifloxacin: a respiratory fluoroquinolone

@nl

type

Item

label

Moxifloxacin: a respiratory fluoroquinolone

@en

Moxifloxacin: a respiratory fluoroquinolone

@nl

prefLabel

Moxifloxacin: a respiratory fluoroquinolone

@en

Moxifloxacin: a respiratory fluoroquinolone

@nl

P1476

Moxifloxacin: a respiratory fluoroquinolone

@en

P2860

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections.

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.

Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic

Antibiotic use in patients admitted with acute exacerbations of chronic obstructive pulmonary disease.

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

P304

1755-1772

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.9.10.1755

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Marc Miravitlles

Antonio Anzueto

P577

2008-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18570608

http://www.w3.org/2001/XMLSchema#string